The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.